Caribou Biosciences’ CEO on working toward a pivotal trial in 2nd line LBCL
Rachel Haurwitz describes recent data and the durability profile of Caribou’s allogeneic CAR-T product as the company plans to discuss a pivotal trial design with FDA.
top of page
Follow BiotechTV
Also look for unique social pages for BiotechTV U.
.png){kind=logo}
Sponsor Spotlight
.png){kind=logo}
The NYSE is the world’s largest stock exchange, offering icons and entrepreneurs the opportunity to raise capital and change the world. Our listed companies form a powerful community committed to good governance and societal impact. Industry-leading trading technology, combined with the guidance of experienced traders creates higher market quality for NYSE-market participants
bottom of page
コメント